Abstract

PRE FORMULATION, FORMULATION AND EVALUATION STUDIES ON ACTIVITY OF DIABETIC DRUG VILDAGLIPTIN

K. Srikanth Reddy*, Dr. P. Vasanth Kumar, P. Priyanka, P. Mythri, C. Sneha, M. Aswani, E. Prakashitha, S. Abdul Jaffar and S. Abrar Ahamed

ABSTRACT

Vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, is widely used for the management of type 2 diabetes mellitus (T2DM). This study focuses on the formulation and evaluation of vildagliptin 50 mg tablets to ensure optimal drug release, stability, and therapeutic efficacy. Various formulations were prepared using direct compression and wet granulation techniques, incorporating different excipients such as binders, diluents, and disintegrants to achieve the desired tablet characteristics. The prepared tablets were evaluated for pre-compression parameters (bulk density, tapped density, angle of repose) and post-compression parameters (hardness, friability, weight variation, drug content uniformity, disintegration time, and in vitro dissolution profile). Among the developed formulations, the optimized batch exhibited satisfactory hardness, rapid disintegration, and a dissolution profile comparable to the marketed formulation. Stability studies confirmed the formulation's robustness under accelerated conditions. The study concludes that an optimized formulation of vildagliptin 50 mg tablets can be successfully developed withImproved drug release and stability, ensuring effective glycemic control in diabetic patients.

Keywords: .